Search results
Results From The WOW.Com Content Network
Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. [4] For the prevention of cardiovascular disease, statins are a first-line treatment. [4] It is taken by mouth. [4] Common side effects include joint pain, diarrhea, heartburn, nausea, and muscle pains. [4]
High alcohol consumption. Smoking. Obesity. Diabetes. ... Atorvastatin. Rosuvastatin. You may be prescribed a statin for a short period of time, or be prescribed a statin alongside other ...
The most important adverse side effects are muscle problems, an increased risk of diabetes mellitus, and increased liver enzymes in the blood due to liver damage. [ 5 ] [ 65 ] Over 5 years of treatment statins result in 75 cases of diabetes, 7.5 cases of bleeding stroke , and 5 cases of muscle damage per 10,000 people treated. [ 34 ]
“It’s a growing problem. Alcohol is a very simple molecule with very diverse effects on physiology,” explains White. “There aren’t many things the body does that alcohol doesn’t impact.”
The effects of rosuvastatin on low-density lipoprotein (LDL) cholesterol are dose-related. Higher doses were more efficacious in improving the lipid profile of patients with hypercholesterolemia than milligram-equivalent doses of atorvastatin and milligram-equivalent or higher doses of simvastatin and pravastatin.
Statins are effective and considered safe for most people, but they raise the risk of side effects, including muscle aches, liver problems, mental fuzziness and the potential for developing diabetes.
Hepatotoxicity, dermatological side effects, and abuse potential. [7] Aminopyrine: 1999 France, Thailand Risk of agranulocytosis and severe acne. [3] Amobarbital: 1980 Norway Risk of barbiturate toxicity. [3] Amoproxan: 1970 France Dermatologic and ophthalmic toxicity. [3] Anagestone acetate: 1969 Germany Animal carcinogenicity. [3] Antrafenine ...
Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug. In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [ 1 ]